论文部分内容阅读
由北京医科大学基础医学研究所马大龙教授研究小组承担的基因工程白细胞介素-3(Inter leukin-3,IL-3)的研制课题已基本完成实验室研制阶段。重组表达产品经DNA序列分析、N端氨基酸序列分析、免疫学分析、活性分析和鉴定,验证其表达的重组蛋白为IL-3。该项成果于今年5月份在京通过鉴定。人白细胞介素-3又称多集落刺激因子(Multi-CSF),是由T细胞产生的多功能细胞因子。它作用于早期生成的血细胞,对类红细胞,原巨核细胞,中性白细胞及B细胞的生长有激活作用,是造血细胞和免疫细胞的重要调节因子。
The research project of genetic engineering interleukin-3 (Interleukin-3, IL-3) undertaken by Professor Ma Dailong from the Institute of Basic Medical Sciences, Beijing Medical University has basically completed the stage of laboratory development. Recombinant protein was identified by DNA sequence analysis, N-terminal amino acid sequence analysis, immunological analysis, activity analysis and identification, to verify the expression of recombinant protein IL-3. The result was passed in Beijing in May this year. Human interleukin-3, also known as multi-CSF, is a multifunctional cytokine produced by T cells. It acts on the early generation of blood cells, the activation of erythroid cells, megakaryocytes, neutrophils and B cells have an activation, hematopoietic cells and immune cells is an important regulator.